Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
232.34
+18.90 (8.85%)
At close: Apr 14, 2026, 4:00 PM EDT
231.39
-0.95 (-0.41%)
After-hours: Apr 14, 2026, 4:19 PM EDT

Ligand Pharmaceuticals Stock Forecast

Stock Price Forecast

The 7 analysts that cover Ligand Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $246.43, which forecasts a 6.06% increase in the stock price over the next year. The lowest target is $220 and the highest is $277.

Price Target: $246.43 (+6.06%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$220$246.43$243$277
Change-5.31%+6.06%+4.59%+19.22%

Analyst Ratings

The average analyst rating for Ligand Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingNov '25Dec '25Jan '26Feb '26Mar '26Apr '26
Strong Buy344455
Buy333222
Hold000000
Sell000000
Strong Sell000000
Total677677

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$239$243
Strong BuyMaintains$239$243+4.59%Apr 14, 2026
Citigroup
Citigroup
Strong Buy
Maintains
$270$276
Strong BuyMaintains$270$276+18.79%Mar 24, 2026
B of A Securities
B of A Securities
Strong Buy
Initiates
$244
Strong BuyInitiates$244+5.02%Mar 11, 2026
Oppenheimer
Oppenheimer
Buy
Maintains
$275$277
BuyMaintains$275$277+19.22%Feb 27, 2026
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$231$239
Strong BuyMaintains$231$239+2.87%Feb 24, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
272.40M
from 268.09M
Increased by 1.61%
Revenue Next Year
323.96M
from 272.40M
Increased by 18.93%
EPS This Year
9.59
from 6.13
Increased by 56.39%
EPS Next Year
11.89
from 9.59
Increased by 23.99%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
241.54M196.25M131.31M167.13M268.09M272.40M323.96M
Revenue Growth
47.68%-18.75%-33.09%27.28%60.40%1.61%18.93%
EPS
3.32-1.982.94-0.226.139.5911.89
EPS Growth
-----56.39%23.99%
Forward PE
-----24.2419.55
No. Analysts
-----1211
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20262027202820292030
High291.9M360.5M
Avg272.4M324.0M
Low248.2M288.0M

Revenue Growth

Revenue Growth20262027202820292030
High
8.9%
32.3%
Avg
1.6%
18.9%
Low
-7.4%
5.7%

EPS Forecast

EPS20262027202820292030
High15.1223.40
Avg9.5911.89
Low8.168.85

EPS Growth

EPS Growth20262027202820292030
High
146.6%
144.1%
Avg
56.4%
24.0%
Low
33.2%
-7.7%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.